[Problem] To provide a balloon catheter with which it is possible for a balloon to be reliably secured, independently, in a target position without blocking the flow of blood. This balloon catheter has: a flexible outer cylinder shaft; a flexible inner cylinder shaft inserted through the outer cylinder shaft; a balloon that is secured to the outer cylinder shaft and that expands or contracts in the transverse direction due to pressure of an internal fluid fed via a space in the outer cylinder shaft; and a securing member that is disposed on the outer circumferential side of the balloon and that and that increases or decreases in diameter in the transverse direction, independently of the balloon, due to mutual movement of the outer cylinder shaft and the inner cylinder shaft in the longitudinal direction. The distal end part of the inner cylinder shaft and the distal end part of the securing member are secured to each other, the distal end part of the outer cylinder shaft and the rear end part of the securing member are secured to each other, and the securing member has a gap through which an external fluid can pass when the diameter is increased.
The present invention pertains to a composition for enhancing immunogenicity that contains, as an active ingredient, particles containing a modified amphiphilic polymer, said modified amphiphilic polymer being an amphiphilic polymer in which the hydrophobic segment is a poly(hydroxy acid) and the hydrophilic segment is a polysaccharide and to which an immune activator is bound, and an antigen.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Provided is a composition for enhancing immunogenicity that has strong immune activation ability. The composition for enhancing immunogenicity contains, as an active ingredient, a mixture of particles containing an amphiphilic polymer, in which the hydrophobic segment is a poly(hydroxy acid) and the hydrophilic segment is a ß-glucan, and an antigen with an immune activator.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
In the present invention, by linking dolastatin 10 or a derivative thereof to an antibody or fragment thereof having immunological reactivity with CAPRIN-1 protein having an amino acid sequence shown in any one of the even numbered SEQ ID NOs: 2 to 30 or an amino acid sequence having 80% or more sequence identity with such amino acid sequence, the anti-tumoral effect by such antibody or such fragment thereof is enhanced.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
[Problem] To provide a high-quality hollow fiber microporous membrane that is concurrently provided with high levels of gas permeability, gas selectivity, and strength. The present invention is characterized by a hollow fiber microporous membrane wherein the carbon dioxide gas flux is 10×105 to 200×105 (cm3(STP)/cm2/sec/cmHg), the value (carbon dioxide gas flux/nitrogen gas flux) that results from dividing the carbon dioxide gas flux value by the nitrogen gas flux value (cm3(STP)/cm2/sec/cmHg) is 1.3 or greater, and the tensile strength is 0.5 cN/dtex or greater.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
This medicament characterized by containing, together or separately in combination with a HDAC inhibitor, an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein is useful as a medicament for treatment and/or prevention of cancer.
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a medicament for the treatment and/or prevention of cancer, the medicament being characterized by comprising an antibody having an immunological reactivity with CAPRIN-1 protein or a fragment of the antibody and a drug capable of inhibiting the N-glycoside-linked sugar chain synthesis of a glycoprotein which are combined with each other in a blended or separated form.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/7072 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a medicament for the treatment and/or prevention of cancer, the medicament being characterized by comprising an antibody having an immunological reactivity with CAPRIN-1 protein or a fragment of the antibody and an MAPK pathway inhibitor which are combined with each other in a blended or separated form.
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
This medicament characterized by containing an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein together or separately in combination with a pyrimidine drug, a platinum formulation, and an angiogenesis inhibitor is useful as a medicament for treatment and/or prevention of cancer in a cancer patient having a past history of another cancer treatment.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
This medicament characterized by containing an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein together or separately in combination with a topoisomerase I inhibitor is useful as a medicament for treatment and/or prevention of cancer.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
The present invention provides a method for treating a feline with a chronic kidney disease, whereby it becomes possible to prevent the progression of the chronic kidney disease in the feline to IRIS stage 4 or renal death or improve an overall survival rate or an observed survival rate. Provided is a method for treating a feline with a chronic kidney disease, the method comprising administering a preparation containing, as an active ingredient, a compound represented by general formula (I): [wherein R represents a hydrogen atom or a pharmacologically acceptable positive ion] to a feline the chronic kidney disease at stage 3 or 4 according to the severity grading of the International Renal Interest Society (IRIS stage grading) in such a manner that the dosage of the compound represented by general formula (I) becomes 90 to 130 µg per day, thereby preventing the progression to IRIS stage 4 in the feline with the chronic kidney disease or preventing renal death.
A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
A61K 9/42 - Organic coatings containing waxes, higher fatty acids, higher fatty alcohols, or derivatives thereof, e.g. chocolate
A61K 47/44 - Oils, fats or waxes according to two or more groups of ; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Provided are: a resin powder mixture which contains a polyarylene sulfide resin powder and has a gas generation amount of 0.25 wt% or less, a melt flow rate of 5-75 g/10 min and an average particle diameter of 1-100 µm; a method for producing same; and a method for producing a three-dimensional molded product using this resin powder mixture. By using this resin powder mixture, it is possible to obtain a three-dimensional molded product which has few voids and exhibits excellent tensile strength.
B33Y 70/00 - Materials specially adapted for additive manufacturing
B29C 64/153 - Processes of additive manufacturing using only solid materials using layers of powder being selectively joined, e.g. by selective laser sintering or melting
The present invention addresses the problem of providing a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance. The present invention provides a therapeutic or prophylactic agent for cachexia accompanied by ghrelin resistance, the agent containing, as an active ingredient, an opioid ? receptor agonist compound represented by the compound.
The purpose of the present invention is to provide an electrode base material which achieves a good balance among high drainage performance, high gas diffusibility and spring properties, while maintaining adequate electrical conductivity. In order to achieve the above-described purpose, an electrode base material according to the present invention is obtained by filling voids of a carbon fiber sheet with a fluororesin and a fine carbon powder; with respect to the fluorine/carbon ratio (F/C) thereof, among the average (F/C-1) in one surface, the average (F/C-2) in the center plane in the thickness direction, and the average (F/C-3) in the other surface, the ratio of the minimum value (F/Cmin) to the maximum value (F/Cmax) is 0.80 or more; the pore size distribution thereof has at least a first peak that is present within the pore diameter range of not less than 0.5 µm but less than 120 µm, and a second peak that is present within the pore diameter range of not less than 10 nm but less than 0.5 µm; and the ratio of the peak volume (V1) of the first peak to the peak volume (V2) of the second peak, namely V1/V2 is from 1.0 to 7Ø
The present invention provides a carbon sheet favorably used in a gas diffusion electrode, it being possible to prevent said electrode from bending into a gas flow path worked into a separator without degrading electrical resistance in the plane-perpendicular direction. This carbon sheet, with which the purpose described above is achieved, has a first surface and a second surface positioned on the opposite side to the first surface, wherein: when a specific section is divided into 20 equal parts in the thickness direction to create 20 layers, the degree of fiber orientation of the outermost surface layer on the first-surface side is 1.203.00 inclusive; and, taking an area of said layer composed of a continuous layer satisfying a specific condition to be a first-surface-side area and an area of said layer that is not included in the first-surface-side area to be a second-surface-side area, the thickness of the first-surface-side area is 40% or less of the thickness of the entire carbon sheet, and the difference between the average degree of fiber orientation in the second-surface-side area and the degree of fiber orientation in the outermost surface layer of on the first-surface side is greater than 0.10.
POLYELECTROLYTE MOLDED BODY, AND POLYELECTROLYTE MEMBRANE, ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE ELECTRODE ASSEMBLY, SOLID POLYMER-TYPE FUEL CELL, AND WATER ELECTROLYSIS-STYLE HYDROGEN PRODUCTION DEVICE IN WHICH SAID POLYELECTROLYTE MOLDED BODY IS USED
A polyelectrolyte molded body that has superior proton conductivity as well as superior mechanical strength and chemical stability is achieved by a polyelectrolyte molded body that is characterized in that, among the mean period sizes of a phase separation structure as observed by small-angle X-ray scattering, the mean period size in air and the mean period size in water satisfy the following expression: mean period size in water / mean period size in air = 2.20.
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
H01B 1/12 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances organic substances
[Problem] To realize a polymer electrolyte membrane having excellent proton conductivity even in low humidity conditions and also having excellent mechanical strength and chemical stability. [Solution] Provided is a polymer electrolyte membrane comprising a block copolymer having one or more of ionic segments and non-ionic segments. The block copolymer has an ion exchange capacity (meq/g) of more than 2.0 and less than 3.1, the polymer electrolyte membrane has a co-continuous phase separation structure, the average period size (nm) of the co-continuous phase separation structure as observed by a transmission electron microscope is less than 110 nm, and the average period size (nm) and the ion exchange capacity (meq/g) of the co-continuous phase separation structure satisfy the relationship of average period size (nm) / ion exchange capacity (meq/g) = 21.
C25B 1/04 - Hydrogen or oxygen by electrolysis of water
C25B 9/00 - Cells or assemblies of cells; Constructional parts of cells; Assemblies of constructional parts, e.g. electrode-diaphragm assemblies; Process-related cell features
C25B 13/04 - Diaphragms; Spacing elements characterised by the material
C25B 13/08 - Diaphragms; Spacing elements characterised by the material based on organic materials
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
H01B 1/12 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances organic substances
The present invention provides: a simple, non-invasive detection method for assisting in determination of whether a pancreatic cystic tumor is benign or malignant; and a detection kit for use in said method. Specifically, the present invention is: a method for assisting in the determination of a malignant pancreatic cystic tumor, the method including a step for measuring, in vitro, the amount of APOA2-AT protein and/or APOA2-ATQ protein present in a body fluid sample from a subject who has a pancreatic cystic tumor and assisting in the determination of whether the pancreatic cystic tumor is benign or malignant on the basis of the amount; and a kit for assisting in the determination of a malignant pancreatic cystic tumor, the kit being for measuring the amount of APOA2-AT protein and/or APOA2-ATQ protein, and being usable in the aforementioned method.
The purpose of the present invention is to provide a compound having a tetrahydroquinoline skeleton, said compound having ferroptosis inhibitory action and exhibiting a treatment effect or a prevention effect for a disease, disorder, or syndrome related to ferroptosis inhibition such as multiple sclerosis. The present invention provides a tetrahydroquinoline derivative represented by the formula, or a pharmacologically acceptable salt thereof.
C07D 215/04 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 215/12 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D 215/14 - Radicals substituted by oxygen atoms
C07D 215/48 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
20.
WOVEN/KNITTED ARTICLE, MANUFACTURING METHOD, AND TEXTILE PRODUCT
The present invention addresses the problem of obtaining a fabric having superior water absorbency and sweat absorption/rapid drying while having anti-pilling qualities and a cotton-like texture. Moreover, a woven/knitted article and textile product material are obtained having anti-pilling characteristics not obtained in prior fabrics having a high combined fiber rate, functionality such as water absorbency, quick drying, fast drying after laundering, etc., that could not be obtained in prior cotton fabrics, good aesthetic and functional characteristics, and good general physical properties. The present invention is a woven/knitted article, a method for manufacturing same, and a textile product, such that the woven/knitted article comprises one or more fibers selected from synthetic fibers, recycled fibers, and semisynthetic fibers, includes spun yarn including at least 30 mass% of an aliphatic polyamide short fiber A having single-fiber fineness of 0.5-5 dtex and a fiber length of 25-70 mm, and has water absorbency evaluated using a falling-drop method of 10 seconds or less.
D02G 3/04 - Blended or other yarns or threads containing components made from different materials
D03D 15/283 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the material of the fibres or filaments constituting the yarns or threads synthetic polymer-based, e.g. polyamide or polyester fibres
D03D 15/37 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the structure of the fibres or filaments with specific cross-section or surface shape
D03D 15/47 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the structure of the yarns or threads multicomponent, e.g. blended yarns or threads
D04B 1/16 - Other fabrics or articles characterised primarily by the use of particular thread materials synthetic threads
D04B 21/16 - Fabrics characterised by the incorporation by knitting, in one or more thread, fleece, or fabric layers, of reinforcing, binding, or decorative threads; Fabrics incorporating small auxiliary elements, e.g. for decorative purposes incorporating synthetic threads
A soft, textile-shaped bioelectrode that is highly comfortable to wear and does not readily shift. A bioelectrode that has a layered structure that comprises a fibrous base material layer and a conductor layer. The fibrous base material layer is formed from non-conductive fibers. The conductor layer is formed from a conductor that contains carbon black, a urethane resin, and an aqueous thickener.
A61B 5/263 - Bioelectric electrodes therefor characterised by the electrode materials
A61B 5/266 - Bioelectric electrodes therefor characterised by the electrode materials containing electrolytes, conductive gels or pastes
D06M 11/74 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with carbon or compounds thereof with graphitic acids or their salts
D06M 15/263 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of unsaturated carboxylic acids; Salts or esters thereof
D06M 15/564 - Polyureas, polyurethanes or other polymers having ureide or urethane links; Precondensation products forming them
22.
METHOD FOR EVALUATING DEGREE OF PURITY OF PHARMACEUTICAL SUBSTANCE CONTAINED IN COMPOSITE BODY, AND METHOD FOR PRODUCING COMPOSITE BODY
Disclosed is a method that can evaluate the degree of purity of an active pharmaceutical substance contained in a composite body. Also disclosed is a method for producing a composite body in which the degree of purity of an active pharmaceutical substance itself is 95.0% or higher. The method for evaluating purity comprises: a reaction step for reacting, in a polar solvent, a nitrogen-containing nucleophilic agent, such as hydroxylamine, with a composite body in the presence of a protonic acid; and an evaluation step for evaluating, using rapid liquid chromatography, the degree of purity of a reaction mixture obtained in the reaction step. The method for producing a composite body comprises a reaction step for obtaining a composite body by reacting, in a polar solvent, N-(2-hydroxypropyl)methacrylamide polymer with an anthracycline pharmaceutical substance, in the presence of a protonic acid and at 10°C or lower.
A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
The purpose of the present invention is to achieve: a woven/knitted fabric which does not inhibit movement of the body and is especially suitable for use in garments; and a garment which uses this woven/knitted fabric. In order to achieve the purpose, a woven/knitted fabric according to the present invention at least partially contains a false twisted yarn of an eccentric core-sheath polyamide composite fiber that has an equilibrium moisture content of 6.3% or less, while having a stress ratio at 15% elongation of from 0.25 to 2.0 in the warp direction and in the weft direction.
A41D 31/00 - Materials specially adapted for outerwear
D03D 15/37 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the structure of the fibres or filaments with specific cross-section or surface shape
D01F 8/12 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the like; Manufacture thereof from synthetic polymers with at least one polyamide as constituent
D02G 1/02 - Producing crimped or curled fibres, filaments, yarns or threads, giving them latent characteristics by twisting, fixing the twist and backtwisting, i.e . by imparting false twist
D06M 15/564 - Polyureas, polyurethanes or other polymers having ureide or urethane links; Precondensation products forming them
24.
AMELIORATING AGENT OR PROPHYLACTIC AGENT FOR MUSCLE WEAKNESS SYMPTOM IN DISEASE OR SYNDROME ASSOCIATED WITH METABOLIC DISORDER
The present invention addresses the problem of providing an ameliorating agent or a prophylactic agent for a muscle weakness symptom in a disease or a syndrome associated with a metabolic disorder. The present invention provides an ameliorating agent or a prophylactic agent for a muscle weakness symptom in a disease or a syndrome associated with a metabolic disorder, the agent containing a compound having a morphinan backbone structure typified by the below-mentioned compound or a pharmacologically acceptable acid addition salt thereof as an active ingredient.
The present invention relates to a method for separating and recovering a cobalt salt and a nickel salt, the method including a separation step for separating a cobalt salt and a nickel salt from a rare metal-containing aqueous solution that contains at least a cobalt salt and a nickel salt as rare metals by means of a nanofiltration membrane. The nanofiltration membrane is such that the glucose permeability is at least 3 times the sucrose permeability, the sucrose permeability is 10% or less and the isopropyl alcohol permeability is 50% or more, when a 1000 mg/L aqueous glucose solution having a pH of 6.5, a 1000 mg/L aqueous sucrose solution, and a 1000 mg/L aqueous solution of isopropyl alcohol are passed through the filter at an operating pressure of 0.5 MPa and a temperature of 25°C.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
The present invention pertains to a method for recovering a rare metal salt, the method comprising: an acid treatment step for obtaining a rare metal-containing acidic aqueous solution by putting a material containing monovalent and polyvalent rare metals in contact with an acid aqueous solution; a separation step for obtaining permeated water containing the monovalent rare metal and non-permeated water containing the polyvalent rare metal from the rare metal-containing acidic aqueous solution by using a nanofiltration membrane satisfying a specific condition (1); and a concentration step for obtaining non-permeated water having a higher concentration of the monovalent rare metal and permeated water having a lower concentration than the permeated water in the separation step, by using a reverse osmosis membrane.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
Provided is an orthotic device which is capable of achieving locking force and orthotic force necessary against deformation and for functional improvement of a lower limb as well as compliance to friction, oscillation, pressure, and the like caused between a correction site and the orthotic device during motion, and which is easy to wear, does not impair external appearance when worn, maintains appropriate locking force and orthotic force for long periods of time, and allows sustained use. This lower-limb orthotic device comprises a fabric band A1 which covers at least a portion of an ankle part including the malleolus and/or at least a portion of a knee part, a fabric band A2 which covers a foot part including the metatarsal bones, and at least one fabric band B, wherein at least a portion of the fabric band B covers the foot part including the cuboid bone or the fifth metatarsal bone, the fabric band B is disposed so as to be positioned from the foot part including the cuboid bone or the fifth metatarsal bone to the ankle part and/or the knee part, one end of the fabric band B in the longitudinal direction is connected to the fabric band A1 and the other end is connected to the fabric band A2, an interior angle between the fabric band A1 and the fabric band B when the lower-limb orthotic device is worn is 30 to 90°, and at least one of the fabric bands has an elongation rate at a load of 100 N/5 cm of 0.5 to 50% in the width direction and the longitudinal direction or in either one of those directions.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A61H 3/00 - Appliances for aiding patients or disabled persons to walk about
28.
KIT OR DEVICE AND METHOD FOR DETECTING HIPPOCAMPAL ATROPHY
NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (Japan)
Inventor
Kashimura, Chiori
Sudo. Hiroko
Yoshimoto, Makiko
Niida, Shumpei
Ito, Kengo
Shigemizu, Daichi
Kato, Takashi
Nakamura, Akinori
Abstract
The present invention relates to: a kit or device for detecting hippocampal atrophy, the kit or device including a nucleic acid capable of binding specifically to predetermined miRNA, which is a marker for hippocampal atrophy, or to a complementary strand thereof; and a method for detecting hippocampal atrophy, the method including measuring the miRNA in vitro.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
Provided is a biodegradable resin, having an intrinsic viscosity of 1.0 dL/g or more and having a loss ratio of intrinsic viscosity of 10% or more after being processed at 70? and 85% of RH for 6 hr. Also provided is a biodegradable resin, containing a polylactic acid of 70 wt% or more and having a relative biodegradation rate up to 90% or more within 12 months when performing degradability evaluation by home composting at 28? according to conditions specified in ASTM D5338-15. The biodegradable resin has the characteristics of high biodegradation speed and storage stability, is excellent in mechanical property, optical property, and barrier property, is applicable to multiple aspects such as packaging and express transportation, and can be rapidly degraded into micromolecules such as carbon dioxide and water at the end of the service life without polluting the environment. Also provided are a biodegradable resin film using the biodegradable resin and a product thereof, as well as a multilayer film containing the biodegradable resin film and a product thereof.
The present invention addresses the problem of providing a medicinal composition for the treatment and/or prevention of cancer. The present invention provides a medicament for the treatment and/or prevention of cancer in cancer patients who have a past history of another cancer treatment, said medicament being characterized by containing a combination of a pyrimidine drug and carboplatin with an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, either separately or in a combined form.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The purpose of the present invention is to provide: a coating agent that can be applied to various materials without using radiation; and a medical material using same. The present invention provides a coating agent containing a copolymer that includes a monomer unit (unit A) including a Si-O bond, a vinyl carboxylate monomer unit (unit B), and a monomer unit (unit C) having a hydrophilic group.
C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
C08F 226/02 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
C09D 133/26 - Homopolymers or copolymers of acrylamide or methacrylamide
C09D 139/02 - Homopolymers or copolymers of vinylamine
C09D 139/06 - Homopolymers or copolymers of N-vinyl-pyrrolidones
32.
MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER
The present invention addresses the problem of providing a medicament for the treatment and/or prevention of cancer. The present invention provides a medicament for the treatment and/or prevention of cancer in cancer patients who have a past history of another cancer treatment, said medicament being characterized by containing a combination of a pyrimidine drug and cisplatin with an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, either separately or in a combined form.
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
33.
MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER
The present invention addresses the problem of providing a medicament for the treatment and/or prevention of cancer. The present invention relates to a medicament for the treatment and/or prevention of cancer in cancer patients who have a past history of another cancer treatment, said medicament being characterized by containing a combination of an angiogenesis inhibitor or an angiogenesis inhibitor and a taxane drug with an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, either separately or in a combined form.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
34.
MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER
The present invention addresses the problem of providing a medicament for the treatment and/or prevention of cancer. In order to solve the abovementioned problem, the present invention provides a medicament for the treatment and/or prevention of cancer, said medicament being characterized by containing a combination of an immune checkpoint inhibitor with an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, either separately or in a combined form.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
35.
MEDICAMENT FOR TREATMENT AND/OR PREVENTION OF CANCER
The present invention addresses the problem of providing a medicament for the treatment and/or prevention of cancer. The present invention relates to a medicament for the treatment and/or prevention of cancer, said medicament being characterized by containing a combination of a fluorinated pyrimidine drug, a folinic acid drug, and at least one other drug with an antibody or a fragment thereof having an immunological reactivity with a CAPRIN-1 protein, either separately or in a combined form.
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Provided is a drug for preventing dialysis shift or renal death, which, when administered in the form of a sustained-release preparation containing, as an active ingredient, a compound represented by general formula (I) to a specific group of patients, can prevent dialysis shift or renal death. Provided is a drug for preventing dialysis shift or renal death, which comprises an oral sustained-release preparation containing, as an active ingredient, a compound represented by general formula (I), the drug being used in such a manner that the compound represented by general formula (I) is administered at a dose of 220 to 260 µg per day to a primary glomerular disease or nephrosclerosis patient having a serum creatinine level of 2.0 mg/dl or more and less than 3.0 mg/dl and/or nutritional disturbance. [In the formula, R represents a hydrogen atom or a pharmacologically acceptable cation.]
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Provided is a moisture-permeable waterproof fabric capable of reducing the environmental load thereof by being carbon neutral and having a prolonged product lifespan, and which has excellent water repellence and moisture permeability. The moisture-permeable waterproof fabric of the present invention has a porous moisture-permeable waterproof film on at least one surface of the fabric. The polyurethane, from which the moisture-permeable waterproof film is formed, is synthesized by using a polyol containing a polycarbonate diol having a plant-derived component.
SPUNBOND NON-WOVEN FABRIC, FILTER LAMINATED FILTER MATERIAL, FILTER MATERIAL FOR PLEATED FILTER FOR DUST COLLECTOR, PLEATED FILTER FOR DUST COLLECTOR, AND MEDIUM AIR VOLUME PULSE-JET TYPE DUST COLLECTOR
A spunbond non-woven fabric disclosed herein includes a thermoplastic continuous filament including a high melting point component and a low melting point component, is made by partially being bonded, and includes a nonbonded projected part and bonded recessed part. Bending resistance in the machine direction of the spunbond non-woven fabric is from 20 mN to 40 mN. In a non-woven fabric cross-section, a thickness from one surface to another surface of the projected part is tA, a thickness from one surface to another surface of the recessed part is ts, and respective distances from one surface of the projected part to one surface of the recessed part are tc and tn (tc < tn) and the spunbond non-woven fabric has a relation represented by the following formulas (1) and (2):15 0.5 1 - tB/tA < 1.0 (1)0.35 < tc/tD <0.65 (2).
B01D 46/52 - Particle separators, e.g. dust precipitators, using filters embodying folded material
39.
SPUNBOND NON-WOVEN FABRIC, FILTER MATERIAL FOR PLEATED FILTER FOR DUST COLLECTOR, PLEATED FILTER FOR DUST COLLECTOR, AND LARGE AIR VOLUME PULSE-JET TYPE DUST COLLECTOR
This spun-bonded nonwoven fabric is constituted from a thermoplastic continuous filament comprising a high-melting-point component and a low-melting-point component, the stiffness in the MD direction of the spun-bonded nonwoven fabric being 40-80 mN inclusive, and in a cross section of the nonwoven fabric, the thickness tA from one surface to the other surface of a non-fused projecting part, the thickness tB from one surface to the other surface of a recessed section obtained by being fused, and distances from the one surface of the projecting part to the one surface of the recessed section, the distances being defined as tC and tD (where tC < tD), are in the relationships shown in formulae (1) and (2) below. 0.5 = 1 - tB/tA < 1.0 (1) 0.65 < tC/tD < 1.0 (2)
This method for manufacturing a film/catalyst assembly, which is formed by bonding a catalyst layer to an electrolyte film, comprises: a liquid addition step for adding, under an air atmosphere, a liquid to only a surface of a pre-bonding electrolyte film; and a thermocompression bonding step for bonding, by thermocompression bonding, the liquid-added electrolyte film to a catalyst layer. This manufacturing method achieves, with high productivity, in the manufacturing of a membrane-catalyst assembly formed by bonding a polyelectrolyte film to a catalyst layer, both relaxation of thermocompression bonding conditions and improved adhesion between the catalyst layer and the electrolyte film.
H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
H01M 8/1086 - After-treatment of the membrane other than by polymerisation
41.
SPUNBOND NON-WOVEN FABRIC, FILTER MATERIAL FOR PLEATED FILTER FOR DUST COLLECTOR, PLEATED FILTER FOR DUST COLLECTOR, AND LARGE AIR VOLUME PULSE-JET TYPE DUST COLLECTOR
This spunbond nonwoven fabric is constituted by thermoplastic continuous filaments composed of high-melting-point components and low-melting-point components, wherein: the coefficient of variability (CV) in the vapor transmission rate of the spunbond nonwoven fabric is 15% or less; the bending resistance along the machine direction (MD) is 40-80 mN; and in a cross-section of the nonwoven fabric, where the thickness from one surface to another surface of a non-fused projection is tA, the thickness from one surface to another surface of a fused indentation is tB, and the distances from one surface of the projection to one surface of the indentation are tC and tD (tC
A flow channel switching system (1, 1') comprising: a first on-off valve (10) which is disposed between a merging part (6) and a branching part (5) and in a raw water path (4); a second on-off valve (11) which is disposed in a raw-water outward path (7); and a sensor (13) for making a measurement of the condition of water flowing through the raw water path, wherein control is performed so as to open the second on-off valve and close the first on-off valve if a signal indicating that water is flowing in the raw water path is received from the sensor, then a signal indicating that no water is flowing in the raw water path is received, and then, within a predetermined period of time, a signal indicating that water is flowing again in the raw water path is received.
The present invention provides an in vivo temperature control system which comprises a means for monitoring the internal temperature of an organ of the body such as the esophagus and for directly adjusting the temperature of the organ depending on the monitoring. The present invention provides an in vivo temperature control system which comprises a catheter that is capable of being inserted into a living body, a temperature probe which has a temperature sensor and is capable of being inserted into the catheter, a liquid storage unit that stores liquid which has been temperature-controlled, a pump that supplies the liquid from the liquid storage unit to the catheter, and a control unit that controls driving of the pump on the basis of a signal detected from the temperature probe, wherein the control unit controls the pump when the signal reaches a preset threshold, and the pump is driven so as to discharge the liquid inside the liquid storage unit to the outside through the catheter.
A61B 18/12 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by heating by passing a current through the tissue to be heated, e.g. high-frequency current
A61B 1/015 - Control of fluid supply or evacuation
A61F 7/12 - Devices for heating or cooling internal body cavities
The present invention addresses the problem of providing a therapeutic or prophylactic agent that is for cachexia and that exhibits significant efficacy in therapy of cachexia with few side effects. The present invention provides a therapeutic or prophylactic agent that is for cachexia and that contains a combination of a ghrelin receptor agonist and a compound having a morphinan backbone, represented by the following compounds, or a pharmaceutically acceptable acid addition salt thereof.
The present invention addresses the problem of providing a small purification column that has a reduced treated liquid capacity but still achieves low pressure loss and has high adsorptivity. The present invention is a fiber bundle that includes a plurality of porous fibers and satisfies conditions (A)(E). (A) The porous fibers have a solid shape. (B) The arithmetic average roughness (the dry Ra value) of the surface of the porous fibers when dry is 1130 nm. (C) The arithmetic average roughness (the wet Ra value) of the surface of the porous fibers when wet is 1240 nm. (D) The value of the wet Ra value/the dry Ra value is at least 1.05. (E) The linearity of the fiber bundle as represented by (the length of the fiber bundle)/(the length of one porous fiber) is 0.971.00.
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
B01D 15/08 - Selective adsorption, e.g. chromatography
B01D 15/22 - Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the construction of the column
The purpose of the present invention is to provide a pharmaceutical composition that improves the permeability of the skin, membranes, or the like to a drug. The present invention provides a pharmaceutical composition that includes a drug and a temperature-responsive ionic liquid.
The purpose of the present invention is to provide a blood treatment material which can adsorb and remove blood components including activated leukocytes and inflammatory cytokines with high efficiency. The present invention provides a blood treatment material comprising a fibrous or particulate water-insoluble material, wherein the difference between a maximum value (RaA) and a minimum value (RaB) of the arithmetic mean roughness (Ra) of the surface of the water-insoluble material is 0.30 to 1.50 µm as calculated using a laser microscope.
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
B01D 15/00 - Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
B01J 20/22 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising organic material
48.
COMPOSITE POLYMER ELECTROLYTE MEMBRANE, ELECTROLYTE MEMBRANE WITH CATALYST LAYER, MEMBRANE-ELECTRODE ASSEMBLY, AND SOLID POLYMER FUEL CELL
Provided is a composite polymer electrolyte membrane: comprising a polymer electrolyte and a porous substrate; and having a dry tensile modulus per unit width of 100 N/cm or greater and a wet tensile modulus per unit width of 35 N/cm or greater. This electrolyte membrane has improved mechanical properties, and as a result, exhibits good dry-wet cycle durability.
H01M 8/1067 - Polymeric electrolyte materials characterised by their physical properties, e.g. porosity, ionic conductivity or thickness
H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
H01M 8/102 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer
H01M 8/1051 - Non-ion-conducting additives, e.g. stabilisers, SiO2 or ZrO2
H01M 8/106 - Polymeric electrolyte materials characterised by a porous support having no ion-conducting properties characterised by the chemical composition of the porous support
H01B 1/12 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances organic substances
49.
COMPOSITE ELECTROLYTE MEMBRANE, ELECTROLYTE MEMBRANE HAVING CATALYST LAYER ATTACHED THERETO, MEMBRANE-ELECTRODE COMPOSITE, SOLID POLYMER-TYPE FUEL CELL, AND METHOD FOR PRODUCING COMPOSITE ELECTROLYTE MEMBRANE
A composite electrolyte membrane with a composite layer in which a hydrocarbon polymer electrolyte has been combined with a porous fluorine-containing polymer base material, wherein the fractal dimension D representing the distribution of the hydrocarbon polymer electrolyte and the porous fluorine-containing polymer base material in the composite layer is at least 1.7. The purpose of the present invention is to achieve high proton conduction ability and high mechanical durability in a composite electrolyte membrane comprising a hydrocarbon polymer electrolyte and a porous fluorine-containing polymer base material.
H01M 8/1044 - Mixtures of polymers, of which at least one is ionically conductive
H01M 8/106 - Polymeric electrolyte materials characterised by a porous support having no ion-conducting properties characterised by the chemical composition of the porous support
H01M 8/1067 - Polymeric electrolyte materials characterised by their physical properties, e.g. porosity, ionic conductivity or thickness
H01M 8/1081 - Polymeric electrolyte materials characterised by the manufacturing processes starting from solutions, dispersions or slurries exclusively of polymers
H01M 8/1086 - After-treatment of the membrane other than by polymerisation
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
The present invention addresses the problem of providing a sheet for heat exchange elements which has high gas-barrier properties, has high fungal resistance, and has water resistance such that the sheet can be used even under high-humidity conditions. The sheet for heat exchange elements has a multilayer structure comprising a porous base and a resin layer, and has a first surface and a second surface. The outermost layer of the sheet for heat exchange elements on the first-surface side is the resin layer. The resin layer comprises polyvinylpyrrolidone and/or a vinylpyrrolidone copolymer, and contains a fungicide.
B32B 27/18 - Layered products essentially comprising synthetic resin characterised by the use of special additives
B32B 27/04 - Layered products essentially comprising synthetic resin as impregnant, bonding, or embedding substance
B32B 27/28 - Layered products essentially comprising synthetic resin comprising copolymers of synthetic resins not wholly covered by any one of the following subgroups
F24F 3/147 - Air-conditioning systems in which conditioned primary air is supplied from one or more central stations to distributing units in the rooms or spaces where it may receive secondary treatment; Apparatus specially designed for such systems characterised by the treatment of the air otherwise than by heating and cooling by dehumidification with both heat and humidity transfer between supplied and exhausted air
F24F 12/00 - Use of energy recovery systems in air conditioning, ventilation or screening
F24F 13/30 - Arrangement or mounting of heat-exchangers
F28F 21/00 - Constructions of heat-exchange apparatus characterised by the selection of particular materials
B32B 5/18 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by features of a layer containing foamed or specifically porous material
The purpose of the present invention is to provide an orthotic: which achieves both the orthotic force that is required to modify the shape of or improve function of the body, and the ability to track friction, compression and the like between an orthotic site and the orthotic that occurs during operation; and which is easy to fit and does not negatively impact outer appearance when fitted. This orthotic has a region B that expresses orthotic force when the orthotic is fitted. The region B is, with respect to any orthotic site, composed of a region B1 that covers the orthotic site, a region B2 that is a support region for causing orthotic force to act, and a region B3 for coupling the region B1 and the region B2 together. A structure that is used for the region B is a stretchy woven structure. The rate of elongation during a load of 100 N/5 cm is 1.0% to 20% in the warp and weft directions or one of said directions. The orthotic further has a region A that covers the periphery of the orthotic site, and the region A is preferably composed of at least one type of stretchy structure.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
The present invention addresses the problem of providing a notched prepreg capable of reliably obtaining a desired formability. This notched prepreg comprises a uniaxially oriented reinforcing fiber and a matrix resin, and has a notch area in which a plurality of notches that divide the reinforcing fiber are formed. In the notch area, the plurality of notches having substantially the same length projected in the fiber direction are arranged in the form of a plurality of notch rows at approximately regular intervals in the fiber direction, and -1.0
B29C 70/20 - Fibrous reinforcements only characterised by the structure of fibrous reinforcements using fibres of substantial or continuous length oriented in a single direction, e.g. roving or other parallel fibres
B29B 11/16 - Making preforms characterised by structure or composition comprising fillers or reinforcements
C08J 5/04 - Reinforcing macromolecular compounds with loose or coherent fibrous material
C08J 5/24 - Impregnating materials with prepolymers which can be polymerised in situ, e.g. manufacture of prepregs
53.
GAS DIFFUSION ELECTRODE, METHOD FOR PRODUCING THE SAME, AND MEMBRANE ELECTRODE ASSEMBLY
The present invention addresses the problem of providing a gas diffusion electrode which causes less damage to an electrolyte membrane or the like due to fluff in the outer peripheral portion during the production of a membrane electrode assembly. The present invention is a gas diffusion electrode which comprises a conductive porous base material containing carbon fibers and a microporous layer that is formed on the surface of the conductive porous base material, and which satisfies at least one of the requirements (1) and (2) described below. (1) When the gas diffusion electrode is viewed in plan, the number of carbon fibers protruding from an edge by 20 µm or more with respect to the length of the edge is less than 1.0/cm. (2) In a side view of an edge of the gas diffusion electrode, the number of carbon fibers inclined at an angle of 30° or more relative to the in-plane direction of the gas diffusion electrode and having a length of 10 µm or more, with respect to the length of the edge, is less than 1.0/cm.
The present invention provides a prepreg characterized by comprising the following constituent elements [A] to [E] and giving a cured object composed of a reinforcing-fiber layer lying from 8% to 92% in terms of thickness-direction depth from a surface and surface resin layers lying respectively from both surfaces to less than 8% in terms of thickness-direction depth, the reinforcing-fiber layer including both a first epoxy resin composition and 90 mass% or more of the constituent element [A] and the surface resin layers including both a second epoxy resin composition and 85 mass% or more of the constituent element [E]. [A] Carbon fibers [B] Epoxy resins comprising the following constituent elements [b1] and [b2]: [b1] a bi- or lower-functional epoxy resin having, in the molecule, at least one cyclic structure including four or more ring-forming members and having a glycidylamine group bonded to the cyclic structure; and [b2] a tri- or higher-functional epoxy resin [C] A thermoplastic resin having a weight-average molecular weight of 2,000-30,000 g/mol [D] Diaminodiphenyl sulfone [E] Particles having a volume-average particle diameter of 5-50 µm and insoluble in the constituent element [B]
A swim suit 23 which comprises a polyurethane elastic yarn, and which is configured such that: the polyurethane elastic yarn contains 0.5-10% by mass of a cationic high molecular weight compound A that has a number average molecular weight of 2,000 or more, while containing an inorganic chlorine deterioration inhibitor B; the (cationic high molecular weight compound A)/(inorganic chlorine deterioration inhibitor B) mass ratio is within the range of 0.3-3; the polyurethane elastic yarn is provided with a silicone-based oil; and the swim suit fabric has been subjected to a water repellent treatment. It is preferable that the swim suit 23 contains a polyurethane elastic yarn that has a fluorine (F)/carbon (C) ratio of 0.030 or more in the elemental mass concentration on the polyurethane elastic yarn as determined by scanning electron microscope-energy dispersive X-ray spectroscopy (SEM-EDX). Consequently, the present invention provides a swim suit which has high water repellency, low water absorptiveness and high buoyancy.
D01F 6/94 - Monocomponent man-made filaments or the like of synthetic polymers; Manufacture thereof from mixtures of polycondensation products as major constituent with other polymers or low-molecular-weight compounds of other polycondensation products
D06M 15/643 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds containing silicon in the main chain
56.
MOLDED ARTICLE OF CARBON FIBER COMPOSITE MATERIAL AND PRODUCTION METHOD FOR MOLDED ARTICLE OF CARBON FIBER COMPOSITE MATERIAL
The present invention addresses the problem of providing a molded article of a carbon fiber composite material that makes it possible to achieve favorable adhesion, regardless of the adhesive or metal used in combination therewith, and that also makes it possible to maintain adhesive force, even after a long period of time has passed after adhesion. A molded article of a carbon fiber composite material that comprises at least carbon fibers and a resin composition. The molded article of a carbon fiber composite material is characterized in that the surface roughness Ra thereof is 0.01-2 pm and in that the tensile shear adhesive strength (FO) thereof when a metal has been adhered to the surface thereof via an adhesive layer that contains an epoxy compound and is 0.1-3 mm thick is 10-40 MPa.
B29C 70/68 - Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts by incorporating or moulding on preformed parts, e.g. inserts or layers
C08J 7/00 - Chemical treatment or coating of shaped articles made of macromolecular substances
57.
POLYETHYLENE GLYCOL-MODIFIED FORM OF HEPATOCYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF
The purpose of the present invention is to provide a polyethylene glycol-modified form of a hepatocyte growth factor or an active fragment thereof wherein the effect of extending in vivo half life period of polyethylene glycol modification and the maintenance of the physiological activity are both achieved. The present invention provides a polyethylene glycol-modified form of a hepatocyte growth factor or an active fragment thereof wherein one molecule of fork-shaped polyethylene glycol covalently binds to the respective carboxyl terminal regions of two molecules of the hepatocyte growth factor or an active fragment thereof to thereby form a homo dimer.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
The purpose of the present invention is to provide a medical base material for an indwelling cardiovascular device, wherein a special knitted structure, which is formed of multifilaments containing ultrafine fibers, can maintain antithrombotic properties by early endothelialization and the storage property in a sheath catheter and the mechanical strength are improved. The present invention provides a medical base material for an indwelling cardiovascular device, said medical base material comprising a knitted fabric, which is formed of multifilaments comprising 30 wt% or more of ultrafine fibers having a single fiber diameter of 1-10 µm, and heparin, a heparin derivative or a pharmacologically acceptable salt thereof which is chemically bonded to the surface of the ultrafine fibers, wherein the knitted fabric has a basis weight of from 5 mg/cm2 to 20 mg/cm2 and a thickness of 200 µm or less and shows a water permeability under a pressure of 120 mmHg of from 1000 mL/min/cm2 to 10000 mL/min/cm2.
D04B 1/16 - Other fabrics or articles characterised primarily by the use of particular thread materials synthetic threads
A61B 17/12 - Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
A61F 2/01 - Filters implantable into blood vessels
A61F 2/04 - Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
A61L 33/10 - Heparin, heparinoid or derivatives thereof
D04B 21/16 - Fabrics characterised by the incorporation by knitting, in one or more thread, fleece, or fabric layers, of reinforcing, binding, or decorative threads; Fabrics incorporating small auxiliary elements, e.g. for decorative purposes incorporating synthetic threads
D06M 15/03 - Polysaccharides or derivatives thereof
59.
POLYETHYLENE GLYCOL-MODIFIED FORM OF HEPATOCYTE GROWTH FACTOR OR ACTIVE FRAGMENT THEREOF
An objective of the present invention is to provide a variant of a hepatocyte growth factor or active fragment thereof capable of lowering liver tropism and selectively expressing bioactivity in target disease tissue other than liver tissue. The present invention provides a polyethylene glycol modified body, of a hepatocyte growth factor or an active fragment thereof, in which polyethylene glycol is bound, via a protease-sensitive peptide, to the terminus of the hepatocyte growth factor or active fragment thereof.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C07K 17/08 - Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
60.
WATER-REPELLENT WOVEN OR KNITTED ARTICLE, PRODUCTION METHOD FOR SAME, AND GARMENT
The present invention overcomes the problems of the prior art and provides a water-repellent woven article that repels water and has excellent abrasion resistance and durability. This water-repellent woven article is a woven article on which a water repellency treatment has been performed using a water repellent that has a perfluorooctanoic acid (PFOA) concentration of no more than 5 ng/g. The water-repellent woven article includes, as constituent fibers, fibers that have cross-sections that have, at the outer circumference thereof, a plurality of grooves that have a wide part. The size of the grooves in the fibers satisfies formula (1) and formula (2) (in which w1 is the width of the entrance of the groove, w2 is the width of the wide part of the groove, h is the depth of the groove, and d is the diameter of the fiber). After washing 20 times in accordance with JIS L 0217 103, the droplet contact angle between water and the woven article is at least 135°, and the water repellency of the woven article as measured by the spray technique in JIS L 1092 is at least a grade 4. (1) w2/w1=1.3. (2) 0.15=h/d=0.25.
D06M 15/643 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds containing silicon in the main chain
A41D 31/04 - Materials specially adapted for outerwear characterised by special function or use
A41D 31/24 - Resistant to mechanical stress, e.g. pierce-proof
A41D 31/00 - Materials specially adapted for outerwear
D01F 8/04 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the like; Manufacture thereof from synthetic polymers
D03D 15/00 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used
D04B 1/16 - Other fabrics or articles characterised primarily by the use of particular thread materials synthetic threads
D04B 21/00 - Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes
D06M 11/00 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
D06M 13/02 - Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials with non-macromolecular organic compounds; Such treatment combined with mechanical treatment with hydrocarbons
61.
CYCLIC AMINE DERIVATIVE AS AGENT FOR PROMOTING ADVILLIN FUNCTION, AND NOVEL CYCLIC AMINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
The present invention addresses the problem of providing an advillin function promoter that comprises a low-molecular compound and is useful for treating neuroaxonal injury. The present invention provides an advillin function promoter that comprises, as an active ingredient, a cyclic amine derivative typically represented by chemical formula or a pharmacologically acceptable salt thereof.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The present invention discloses an esophageal liquid-supply catheter with which it is possible to efficiently supply a liquid to the esophagus and thereby reduce temperature conduction during heating, cooling, etc., caused by ablation of the esophagus. This esophageal liquid-supply catheter comprises a cylindrical member, a plurality of arms of which the proximal-end parts are secured to a distal-end part of the cylindrical member, and a distal-end tip secured to the distal ends of the arms, the esophageal liquid-supply catheter being such that the plurality of arms are capable of deforming and extending outward in the radial direction of the cylindrical member. For example, a shaft that is inserted into the cylindrical member and has the distal end thereof secured to the distal-end tip is provided, and the shaft is caused to slide toward the proximal-end side relative to the cylindrical member, thereby making it possible to cause the arms to extend radially outward.
The present invention addresses the problem of reducing the introduction of impurities into a gas in a power generation system. This power generation system purifies an anode gas using a separation membrane comprising any of a polyamide, graphene, a metal-organic framework (MOF), and a covalent organic framework (COF), and then feeds the product to a negative electrode.
H01M 8/0662 - Treatment of gaseous reactants or gaseous residues, e.g. cleaning
C01B 3/50 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification
C01B 3/56 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification by contacting with solids; Regeneration of used solids
The present invention separates and recycles hydrogen, from negative-electrode exhaust gas, using a separation membrane containing any one of a polyamide, graphene, a metal organic framework (MOF), and a covalent organic framework (COF).
H01M 8/0662 - Treatment of gaseous reactants or gaseous residues, e.g. cleaning
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
C01B 3/50 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification
C01B 3/56 - Separation of hydrogen or hydrogen containing gases from gaseous mixtures, e.g. purification by contacting with solids; Regeneration of used solids
The present invention refines a positive electrode gas using a separation membrane composed of any one of a polyamide, graphene, a metal organic framework (MOF), and a covalent organic framework (COF), and supplies said gas to a positive electrode.
H01M 8/0662 - Treatment of gaseous reactants or gaseous residues, e.g. cleaning
B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
The present invention addresses the problem of providing a carpet having an excellent antifouling property against both dry soil and wet soil. A carpet (1) comprises pile yarns (4) comprising coated pile single yarns (6), wherein the coated pile single yarns (6) are pile single yarns (8) to which a layer A containing organopolysiloxane and a fluorine compound is attached. The coated pile single yarns (6) have a fineness of 8 to 40 dtex, and the pile yarns (4) have a crimp elongation of 10 to 30%. The carpet (1) has a carpet staining degree (?E) of not more than 30 in an antifouling dry test, and a carpet staining degree (?E) of not more than 30 in an antifouling wet test.
D06M 15/277 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of unsaturated carboxylic acids; Salts or esters thereof containing fluorine
D06M 15/643 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds containing silicon in the main chain
67.
GAS DIFFUSION ELECTRODE, METHOD FOR MANUFACTURING GAS DIFFUSION ELECTRODE, MEMBRANE ELECTRODE ASSEMBLY, AND FUEL CELL
The objective of the present invention is to provide a low-cost gas diffusion electrode having good electricity generation performance, with which drawbacks of the prior art can be overcome, and with which dry-up resistance and flooding resistance can be achieved simultaneously. The present invention provides a gas diffusion electrode having a microporous layer including electrically conductive fine particles on at least one surface of an electrically conductive porous substrate, wherein the proportion (number basis) of fine holes having a circularity at least equal to 0.5, among fine holes having a surface area at least equal to 0.25µm2, as observed in a cross section in the thickness direction of the microporous layer, is at least equal to 50% and at most equal to 100%.
Disclosed are: a non-specific binding inhibitor, which efficiently inhibits cross hybridization between a target nucleic acid and a nucleic acid having a sequence similar to the complementary chain thereof in the case of detecting the target nucleic acid by hybridization and the qualities of which are consistent from production lot to production lot; and a nucleic acid hybridization method using the non-specific binding inhibitor. The inhibitor of non-specific binding of nucleic acid comprises a nucleic acid that has a base length of 2-11 bases and shows a guanine or methylated guanine content of 70% or greater relative to the total base sequence.
Provided is a wearable capable of detecting a low-noise and stable signal for comfortably and easily diagnosing, via electrocardiogram analysis or the like, diseases in subjects of various builds and sizes during the subjects' everyday lives, including while walking and climbing stairs, over a long period of at least one week. A biological signal monitoring wearable according to the present invention is characterized by comprising: a biological signal measurement instrument; at least two electrodes to be in contact with skin; and a wearable body in which a conductive body connecting the biological signal measurement instrument and the electrodes is supported by a fabric member, and an elastic body is fixed to a torso part of the fabric member, the elastic body having a length that is 30% to 60%, inclusive, of the circumference of the torso around the subject's epigastrium.
A microporous layer of the present invention enables obtaining a fuel cell that can be produced with high productivity and that exhibits high power generation performance and high durability. The present invention is a gas diffusion electrode base material having a microporous layer on one side of an electroconductive porous base material, wherein the electroconductive porous base material comprises carbon fibers and a carbonized resin, and has a density of 0.25-0.39 g/cm3 and a pore modal diameter falling within a range of 30-50 µm. The microporous layer comprises a carbonaceous powder and a fluorine resin, and has a surface roughness of 2.0-6.0 µm, a porosity of 50-95%, and a pore modal diameter of 0.050-0.100 µm.
The present invention addresses the problem of providing a gas diffusion layer that improves power generation performance of a fuel cell. This gas diffusion layer includes a carbon sheet and a microporous layer on at least one surface of the carbon sheet. With A defined as the "in-plane permeability coefficient of oxygen" of oxygen that permeates the inside of the gas diffusion layer in an in-plane direction, B defined as the "electrical resistance" when the gas diffusion layer is compressed at 2 MPa in the perpendicular direction, and C defined as the "compatibility index of in-plane permeability coefficient of oxygen and electric resistance," where C is a number obtained by adding 310 to a number obtained by subtracting B multiplied by 60 from A, when a region having a width of 10 mm and a depth of 3 mm is arbitrarily selected in the gas diffusion layer and compressed at a pressure of 0.5 MPa in a perpendicular direction from one side of the gas diffusion layer, the relationship C is 0 or more is satisfied.
An object of the present invention is to provide a cylindrical body for an implant capable of maintaining a high patency rate, by achieving a good antithrombogenicity, a low swelling property and a low Young's modulus. The present invention provides a cylindrical body for an implant, including: a cylindrical substrate having an elongation rate in the longitudinal direction, as measured under a tensile load of 20 N, of from 5 to 100%; and a block copolymer composed of a polyalkylene glycol block(s) and a polyhydroxyalkanoic acid block(s); wherein the ratio of the mass of the polyalkylene glycol with respect to the total mass of the block copolymer is from 5 to 25%; and wherein a film composed of the block copolymer has a Young's modulus of 200 MPa or less.
A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
A61L 31/14 - Materials characterised by their function or physical properties
A61L 33/00 - Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
73.
MUTANT STRAIN OF TRICHODERMA REESEI AND METHOD FOR PRODUCING PROTEIN USING SAME
The present invention is a mutant strain of Trichoderma reesei in which the function of a polypeptide comprising an amino acid sequence represented by any of SEQ ID NOs: 4-6 is deleted or decreased, and a method for producing a high level of protein by culturing the mutant strain in medium containing lactose.
The present invention provides: a Trichoderma reesei mutant strain having such a mutation that the function of a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2 is lost or decreased; and a method for the high-throughput production of a protein, comprising culturing the mutant strain.
Provided is a fiber-reinforced thermoplastic resin comprising a continuous fiber substrate made from continuous reinforcing fibers, and a thermoplastic resin applied to the surface thereof. The thermoplastic resin coats the entire surface of the continuous fiber substrate in a solidified state, and impregnates the continuous fiber substrate while leaving voids therein, with these voids being formed intermittently in the direction in which the fibers are arranged. Also provided is a laminate using the fiber-reinforced thermoplastic resin substrate. With regard to the fiber-reinforced thermoplastic resin substrate having a thermoplastic resin as a matrix, the surface of the fiber-reinforced substrate is coated by the thermoplastic resin with a high uniformity, and by impregnating the fiber-reinforced substrate with the matrix resin uniformly while leaving voids therein, a fiber-reinforced thermoplastic resin substrate is provided which has excellent shaping properties and ease of handling.
Provided is a method for producing thermoplastic resin-impregnated sheet-form reinforcing fiber bundle obtained by impregnating reinforcing fibers made from continuous fibers with a thermoplastic resin, said method comprising: an application step in which a sheet-form reinforcing fiber bundle obtained by arranging reinforcing fibers made from continuous fibers in one direction is passed through an application unit which stores thermoplastic resin, and the thermoplastic resin is applied to the sheet-form reinforcing fiber bundle to constitute a thermoplastic resin-impregnated sheet-form reinforcing fiber bundle; a further impregnation step in which the applied thermoplastic resin is further impregnated into the interior of the thermoplastic resin-impregnated sheet-form reinforcing fiber bundle; and a shaping step in which the thermoplastic resin-impregnated sheet-form reinforcing fiber bundle is shaped and solidified by cooling. In the application step, the sheet-form reinforcing fiber bundle is passed downward in a vertical direction to apply thermoplastic resin to a band-shaped reinforcing fiber bundle, and in the application step and the further impregnation step, the thermoplastic resin is heated to a temperature of at least the melting point +30°C, and the viscosity of the thermoplastic resin in the heated state is 5-200 Pa·s. With regard to the method for producing a thermoplastic resin-impregnated sheet-form reinforcing fiber bundle, continuous production which curbs the occurrence of fluff and eliminates fluff blockages is possible, and it is also possible to efficiently impregnate the sheet-form reinforcing fiber bundle with a thermoplastic resin, and enable high-speed production.
A multiaxial fabric resin base material including a multiaxial fabric base material laminate impregnated with a thermosetting resin (B), the multiaxial fabric base material laminate including fiber bundle sheets layered at different angles, the fiber bundle sheets including unidirectionally aligned fiber bundles stitched with stitching yarns composed of a thermoplastic resin (A), the multiaxial fabric base material laminate being penetrated in the thickness direction by other bodies of the stitching yarns, and being stitched with the other bodies of the stitching yarns such that the yarns reciprocate at predetermined intervals along the longitudinal direction, the thermoplastic resin (A) constituting the stitching yarns having a softening point, the softening point being higher than the resin impregnation temperature of the thermosetting resin (B). A multiaxial fabric resin base material which has excellent resin impregnation properties, high durability (hydrolysis resistance and heat deterioration resistance), and composite material mechanical properties, and which is capable of improving compressive strength after impact (CAI), is provided.
C08J 5/04 - Reinforcing macromolecular compounds with loose or coherent fibrous material
D04H 3/115 - Non woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating with bonds between yarns or filaments made mechanically by applying or inserting filamentary binding elements
B32B 5/28 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer impregnated with or embedded in a plastic substance
D03D 1/00 - Woven fabrics designed to make specified articles
D04H 3/04 - Non woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments in rectilinear paths, e.g. crossing at right angles
C08L 67/00 - Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
78.
REINFORCING FIBER TAPE MATERIAL AND PRODUCTION METHOD THEREOF, REINFORCING FIBER LAYERED BODY AND FIBER REINFORCED RESIN MOLDED BODY USING REINFORCING FIBER TAPE MATERIAL
A reinforcing fiber tape material having a reinforcing fiber strand, used for resin injection molding, characterized in that the tape material is formed by being restrained and integrated with reinforcing fibers forming the reinforcing fiber strand or/and a plurality of reinforcing fiber strands with each other by a resin material arranged on at least one of surfaces of the reinforcing fiber strand and another resin material arranged on one of the surfaces different in softening point from the resin material, and both the resin materials have matrix resin permeability, a production method thereof, and a reinforcing fiber layered body and a fiber reinforced resin molded body using the reinforcing fiber tape material. In particular, when a sheet base material or a pre-formed body is made by a fiber placement method, adhesion to and placement in a tool are facilitated, and resin flow time in a resin injection step can be shortened. Further, a reinforcing fiber tape material having a good formability and a good resin impregnation property in a subsequent molding step, and layered sheet base material and molded article thereof, can be obtained.
B29C 70/16 - Fibrous reinforcements only characterised by the structure of fibrous reinforcements using fibres of substantial or continuous length
B29C 70/50 - Shaping or impregnating by compression for producing articles of indefinite length, e.g. prepregs, sheet moulding compounds [SMC] or cross moulding compounds [XMC]
B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
B32B 27/12 - Layered products essentially comprising synthetic resin next to a fibrous or filamentary layer
79.
POLYAMIDE RESIN COMPOSITION FOR EXTRUSION MOLDED PRODUCTS EXPOSED TO HIGH-PRESSURE HYDROGEN, AND EXTRUSION MOLDED PRODUCT
The purpose of the present invention is to provide a polyamide resin composition which has excellent extrusion moldability and retention stability, can suppress the thickness deviation of a molded product, and can be used to obtain an extrusion molded product in which the occurrence of defects is suppressed even after repeated charging and release of high-pressure hydrogen. Provided is a polyamide resin composition for extrusion molded products exposed to high-pressure hydrogen, the polyamide resin composition being obtained by combining 0.005-1 part by weight of a metal halide (C) with 100 parts by weight in total of 70-99 parts by weight of a polyamide 6 resin (A) and 1-30 parts by weight of an impact resistant material (B), wherein the polyamide resin composition has a molten tension of at least 20 mN as measured at 260°C, and a take-up speed at break of at least 30m/min as measured at 260°C.
C08L 23/26 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers modified by chemical after-treatment
F17C 1/16 - Pressure vessels, e.g. gas cylinder, gas tank, replaceable cartridge constructed of plastics materials
80.
MUTANT OF TRICHODERMA FILAMENTOUS FUNGUS AND METHOD FOR PRODUCING PROTEIN
The present invention relates to: a mutant of a trichoderma filamentous fungus having a mutation that results in lost or lowered function of a beta-adaptin large subunit, or a mutation in an amino acid sequence that forms the beta-adaptin large subunit; and a method for producing a protein while maintaining a low viscosity in a culture solution during culturing by using the mutant.
An object of the present invention is to provide a carrier for adsorbing organic matter, which achieves both of adsorption ability for organic matter and suppression of pressure increase. The present invention provides a carrier for adsorbing organic matter, comprising a sea-island type solid composite fiber, wherein the pore volume is 0.05 to 0.5 cm3/g and the fiber diameter is 25 to 60 µm.
A61M 1/36 - Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
B01D 15/00 - Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
B01J 20/28 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
D01F 8/06 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the like; Manufacture thereof from synthetic polymers with at least one polyolefin as constituent
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
82.
POLYAMIDE RESIN COMPOSITION FOR BLOW-MOLDED PRODUCTS EXPOSED TO HIGH-PRESSURE HYDROGEN, AND BLOW-MOLDED PRODUCT
The purpose of the present invention is to provide a polyamide resin composition which has excellent blow moldability and retention stability, can suppress the residual strain of a molded product from locally increasing, and can be used to obtain a blow-molded product in which the occurrence of defects is suppressed even after repeated charging and release of high-pressure hydrogen. Provided is a polyamide resin composition for blow-molded products exposed to high-pressure hydrogen, the polyamide resin composition being obtained by combining 0.005-1 part by weight of a metal halide (C) with 100 parts by weight in total of 70-99 parts by weight of a polyamide 6 resin (A) and 1-30 parts by weight of an impact resistant material (B), wherein the polyamide resin composition has a molten tension of at least 20 mN as measured at 260°C, and a take-up speed at break of at least 50 m/min as measured at 260°C.
C08L 23/26 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers modified by chemical after-treatment
83.
METHOD OF MANUFACTURING AND DEVICE FOR MANUFACTURING MEMBRANE-CATALYST ASSEMBLY
The present invention addresses the problem of providing a method of manufacturing a membrane-catalyst assembly in which a catalyst layer is bonded to a polymer electrolyte membrane, the method being capable of achieving both relaxed thermocompression bonding conditions and improvement in adhesion between the catalyst layer and the electrolyte membrane with high productivity when manufacturing the membrane-catalyst assembly. Provided is a method of manufacturing a membrane-catalyst assembly in which a catalyst layer is bonded to a electrolyte membrane, the method including a liquid applying step of applying liquid on a surface of the catalyst layer before bonding, and a thermocompression bonding step of bonding the catalyst layer to which the liquid has been applied to the electrolyte membrane by thermocompression bonding.
H01M 8/1004 - Fuel cells with solid electrolytes characterised by membrane-electrode assemblies [MEA]
H01M 8/1023 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer having only carbon, e.g. polyarylenes, polystyrenes or polybutadiene-styrenes
Provided is a method in which a reference miRNA is identified that exhibits a change in the amount thereof present in a body fluid specimen depending on changes in the quality of the body fluid specimen, and the quality of the body fluid specimen is evaluated using the amount of the reference miRNA present in the specimen as an index.
This fiber-reinforced polymer alloy substrate, in which continuous reinforcement fibers are arranged in parallel and are impregnated with a polymer alloy, is characterized in that: a polymer alloy obtained by combining thermoplastic resins of at least two types is used as the polymer alloy; the fiber volume content ratio is in the range 4070% by volume; and the dispersion parameter D of the fibers is at least 90%. In the obtained fiber-reinforced polymer alloy substrate, the reinforcement fibers are dispersed with high homogeneity, and mechanical characteristics and heat resistance are high and expressed stably with low variation.
A fiber-reinforced resin base material which is obtained by impregnating a continuous reinforcing fiber or a reinforcing fiber material, wherein discontinuous fibers are dispersed, with a resin composition that has a single glass transition temperature before and after one-hour heating at 400°C, and which is configured such that the resin composition is composed of (A) a thermoplastic resin that has a glass transition temperature of 100°C or more and (B) a thermoplastic resin that has a glass transition temperature of less than 100°C. Consequently, the present invention provides a fiber-reinforced resin base material which exhibits excellent impregnation ability and thermal stability, while having few voids, thereby achieving good surface quality and high heat resistance.
In order to provide a spunbond nonwoven fabric for use in filters that has excellent rigidity, folding resistance and basis weight uniformity, and that also has excellent dust capture performance and mechanical properties, this spunbond nonwoven fabric, which is configured from thermoplastic continuous filaments and has a partially fused portion, has a nonwoven fabric stiffness of 2-100 mN, a basis weight CV value of less than or equal to 5%, and a basis weight of 150-300 g/m2.
D04H 3/16 - Non woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of strengthening or consolidating with bonds between thermoplastic yarns or filaments produced by welding with bonds between thermoplastic filaments produced in association with filament formation, e.g. immediately following extrusion
The purpose of the present invention is to stably maintain high separation performance of a separation membrane having a separation layer comprising a compact carbon layer. The present invention is a separation membrane having a separation layer comprising a compact carbon layer, wherein particles are attached to the compact carbon layer, recesses are present in the compact carbon layer, and the particles are at least partially stuck in the recesses.
The present invention relates to: a Trichoderma filamentous fungus mutant strain having reduced functionality of a polypeptide formed by an amino acid sequence of SEQ ID NO: 2; and a high-producing method for a protein by using the mutant strain.
This invention according to one embodiment provides a kit, a device, and a method for detecting bladder cancer. This invention according to one embodiment relates to: a kit or a device that is for detecting bladder cancer and that contains a nucleic acid capable of selectively binding with the miRNA, or a complementary strand thereof, in a sample of a subject; as well as to a method for detecting bladder cancer, comprising in vitro determination of the miRNA.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The purpose of the present invention is to provide a composite electrolyte membrane which has excellent chemical resistance and can maintain sufficient mechanical strength even under conditions of high humidity and high pressure, which are the operating conditions for electrochemical hydrogen pumps and water electrolyzers. This composite electrolyte membrane, which is for achieving said purpose, has a composite layer obtained by combining a polyelectrolyte with a mesh woven material that satisfies (1) and (2) and comprises liquid crystal polyester fibers or polyphenylene sulfide fibers. (1): Mesh thickness (µm)/fiber diameter (µm)?2Ø (2): Opening (µm)/fiber diameter (µm)?>?1Ø
C08G 63/60 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from the reaction of a mixture of hydroxy carboxylic acids, polycarboxylic acids and polyhydroxy compounds
C25B 13/08 - Diaphragms; Spacing elements characterised by the material based on organic materials
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
92.
METHOD FOR PRODUCING HAIRPIN SINGLE-STRANDED RNA MOLECULE
The present invention provides a method for producing a hairpin single-stranded RNA molecule that inhibits the expression of a target gene. The method includes (i) an annealing step of annealing a first single-stranded oligoRNA molecule with a second single-stranded oligoRNA molecule and (ii) a ligation step of ligating, using a ligase in the Rnl2 family, the 3' end of the first single-stranded oligoRNA molecule with the 5' end of the second single-stranded oligoRNA molecule. The sequence produced by the ligation of the first single-stranded oligoRNA molecule with the second single-stranded oligoRNA molecule contains a gene expression-inhibiting sequence directed to the target gene.
C12N 15/00 - Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
93.
TRICHODERMA REESEI MUTANT AND PROTEIN PRODUCTION METHOD
The present invention relates to: a Trichoderma reesei mutant wherein a polypeptide comprising an amino acid sequence represented by SEQ ID NO:2 has a reduced function; and a method for enhanced production of a protein using the mutant.
In order to provide a fiber-reinforced resin which is effective in reducing burrs while avoiding problems such as incomplete filling or incomplete resin impregnation, and exhibits excellent mechanical properties and cavity filling properties, even when press-molding a three-dimensional shape having a thick section and/or a change in thickness caused by a projection or the like, this method for producing a fiber-reinforced resin by press-molding a preform of a prepreg comprising reinforcing fibers and a heat-curable resin is characterized: by including (a) a preform preparation step for preparing a preform, (b) a positioning/preheating step for positioning and preheating the preform in a die, (c) a pressing step for deforming the preform into the product shape, and (d) a curing step for applying pressure to while curing the preform; and in that the degree ae of curing of the heat-curable resin in a specific section of the preform at the time of starting the (c) pressing step is greater than the degree ai of curing of the heat-curable resin in regions other than the specific section of the preform at said time.
The purpose of the present invention is to provide a biodegradable block copolymer which combines high conformability with excellent degradability. The present invention provides a block copolymer which comprises a poly(alkylene glycol) block and a poly(hydroxyalkanoic acid) block, wherein the proportion by mass of the poly(alkylene glycol) block to the whole mass is 10-60%, the block copolymer having a carbon-nucleus relaxation time T1? regarding the carbonyl carbon atom of 20 ms or less and satisfying expression 1. ?=?1×?2=20 (expression 1) ?1 is the degree of crystallization of the poly(alkylene glycol) block. ?2 is the degree of crystallization of a poly-A block, where A is a repeating unit, among the repeating units contained in the poly(hydroxyalkanoic acid) block, that is the highest in the degree of crystallization of the homopolymer made up of the same repeating units alone.
In order to provide a nonwoven fabric sheet with high flame shielding performance, heat insulation and wear resistance, this nonwoven fabric is characterized by including at least one flameproof layer formed from a web containing non-melting fibers A which have a high-temperature shrinkage rate of less than or equal to 3% and a thermal conductivity in conformance with ISO 22007-3 (2008) of less than or equal to 0.060 W/m*K, wherein said flameproof layer is formed by combining with a scrim layer that contains carbonized heat resistant fibers B which have an LOI value in conformance with JIS K 7201-2 (2007) of greater than or equal to 25.
D04H 1/4374 - Non-woven fabrics formed wholly or mainly of staple fibres or like relatively short fibres from fleeces or layers composed of fibres without existing or potential cohesive properties characterised by the use of certain kinds of fibres insofar as this use has no preponderant influence on the consolidation of the fleece using different kinds of webs, e.g. by layering webs
B32B 5/26 - Layered products characterised by the non-homogeneity or physical structure of a layer characterised by the presence of two or more layers which comprise fibres, filaments, granules, or powder, or are foamed or specifically porous one layer being a fibrous or filamentary layer another layer also being fibrous or filamentary
97.
PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF CANCER
The present invention provides a pharmaceutical product for treatment and/or prevention of cancer, characterized by including imiquimod together or separately in combination with an antibody, or a fragment thereof, having immunological reactivity with a CAPRIN-1 protein. With this pharmaceutical product, it is possible to treat and/or prevent cancer that specifically expresses the CAPRIN-1 protein on a cell surface.
A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61K 31/4745 - Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61P 35/02 - Antineoplastic agents specific for leukemia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention addresses the problem of providing an agent for inhibiting a rise in the intraneuronal calcium concentration. The present invention provides an agent for inhibiting a rise in the intraneuronal calcium concentration, said agent containing a cyclic amine derivative represented by the chemical formula below or a pharmacologically acceptable salt thereof as an active ingredient.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
A61P 25/00 - Drugs for disorders of the nervous system
The purpose of the present invention is to provide an electrolyte membrane that has improved bondability with a catalyst layer and that achieves good power generation performance, without the electrolyte membrane undergoing a physical treatment and without any loss of surface modification effect. To achieve the foregoing, this electrolyte membrane comprises a polymer electrolyte and a nonionic fluorochemical surfactant.
H01M 8/1044 - Mixtures of polymers, of which at least one is ionically conductive
H01M 8/102 - Polymeric electrolyte materials characterised by the chemical structure of the main chain of the ion-conducting polymer
H01M 8/1051 - Non-ion-conducting additives, e.g. stabilisers, SiO2 or ZrO2
H01M 8/106 - Polymeric electrolyte materials characterised by a porous support having no ion-conducting properties characterised by the chemical composition of the porous support
C08G 61/10 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aromatic carbon atoms, e.g. polyphenylenes
C08G 65/48 - Polymers modified by chemical after-treatment
H01B 1/06 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
The present invention provides a fluid separation membrane which is capable of maintaining separation performance for a long period of time. The present invention is a fluid separation membrane which comprises a separation layer that is composed of a dense layer, and wherein 2-10,000 ppm in total of monocyclic or bicyclic aromatic compounds that are in a liquid state or in a solid state at 16°C at atmospheric pressure and 10-250,000 ppm of water are adsorbed.
B01D 69/02 - Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties